BetterLife Pharma Inc. BETRF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.12% | -30.17% | -60.59% | -55.55% | -45.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.50% | -34.73% | -62.34% | -59.71% | -52.75% |
| Operating Income | -10.50% | 34.73% | 62.34% | 59.71% | 52.75% |
| Income Before Tax | -333.82% | -9.38% | 58.64% | 48.09% | 82.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -333.82% | -9.38% | 58.64% | 48.09% | 82.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 495.12% | 489.36% | -82.81% | 108.51% | 98.85% |
| Net Income | -327.94% | -7.55% | 57.94% | 56.11% | 83.70% |
| EBIT | -10.50% | 34.73% | 62.34% | 59.71% | 52.75% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -285.37% | 13.46% | 66.82% | 63.98% | 86.69% |
| Normalized Basic EPS | -63.93% | 42.00% | 71.67% | 68.51% | 75.00% |
| EPS Diluted | -157.14% | 26.77% | 68.29% | 56.09% | 80.19% |
| Normalized Diluted EPS | -63.93% | 42.00% | 71.67% | 68.51% | 75.00% |
| Average Basic Shares Outstanding | 15.09% | 19.22% | 17.73% | 16.75% | 16.10% |
| Average Diluted Shares Outstanding | 11.51% | 15.31% | 13.76% | 12.69% | 19.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |